# Pemetrexed as First Line Chemotherapy for Advanced Breast Cancer

> **NCT00065533** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 92 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** pemetrexed

## Key facts

- **NCT ID:** NCT00065533
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-05
- **Primary completion:** —
- **Final completion:** 2005-06
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2007-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00065533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00065533, "Pemetrexed as First Line Chemotherapy for Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00065533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*